Kemin Industries, the US multinational manufacturer of feed and food additives for animal and human health, has acquired the majority stake in an Egyptian veterinary vaccine maker.
The company first invested in Cairo-based MEVAC in 2010, with further investments over subsequent years, gaining the right in 2019 to distribute its vaccines globally – until then they were restricted to the Arabic-speaking countries in the Middle East.
It says the move expands Kemin’s portfolio in the global animal vaccine market, through access to MEVAC’s modern vaccine plant with production and R&D capabilities to support future growth. The investment also increases Kemin’s shareholding in MEVAC’s sister company UVAC, also based in Egypt, which specialises in foot-and-mouth disease and tissue-culture vaccines for animals, as well as human vaccines.
“We entered into a partnership with MEVAC over a decade ago and are thrilled to become the majority shareholder,” says Chris Nelson, president and chief executive Kemin Industries. “Kemin and MEVAC share the goal of transforming lives and creating a sustainable future – one in which non-antibiotic alternatives are becoming more and more important to customers. By extending our partnership to MEVAC’s sister company, UVAC, we can do even more to bring our innovations to animal vaccines.”